



PRESS RELEASE

Berlin, 2 July 2018

Klaus Pellengahr new General Manager of Organobalance-Novozymes Berlin Professor Dr. Christine Lang will continue as a consultant for Novozymes.

The German microbial research company Organobalance and the Danish biotechnology company Novozymes A/S are making organizational changes at Organobalance-Novozymes Berlin. Professor. Dr. Christine Lang will step down as General Manager on July 1, 2018. In a planned transition, Dr. Klaus Pellengahr, until now Director for Business Development at Organobalance, will take over the position as General Manager.

Professor Dr. Christine Lang founded Organobalance, and she is to continue as a consultant for Novozymes within the microbial-applications space. She has decided to focus on her work in academic networks and on bioeconomy topics while further engaging with the scientific advisory boards that she is a member of, like first vice president of the Association for General and Applied Microbiology (Vereinigung für Allgemeine und Angewandte Mikrobiologie, VAAM) and chair of the German Bioeconomy Council.

“Professor Lang and her team have further enhanced our world-class R&D capabilities within microbials, especially within applications for feed, food, animal and human health”, says Sebastian Søderberg, Vice President for Business Incubation & Acquisitions at Novozymes. This journey will be continued by Klaus Pellengahr and the rest of Organobalance.

“I look forward to take up my new role and be working together with Novozymes on doing groundbreaking research and innovation,” says Dr. Klaus Pellengahr. In addition to his new role as General Manager for the Berlin site, Klaus Pellengahr will also contribute with research and development of new microbiological processes and products for food and dietary supplements.

Organobalance GmbH became a part of Novozymes in September 2016, and it will continue its research, innovation and business development in Berlin. “Berlin is a key biotechnology location; it is here that Organobalance managed to establish successful contacts to the scientific and policy-making communities in recent years and it is a hub for biotech talent,” says Sebastian Søderberg.



About Novozymes

Novozymes is the world leader in biological solutions. Together with customers, partners and the global community, we improve industrial performance while preserving the planet's resources and helping build better lives. As the world's largest provider of enzyme and microbial technologies, our bioinnovation enables higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel and many other benefits that we rely on today and in the future.

We call it Rethink Tomorrow. www.novozymes.com

About Organobalance – Novozymes Berlin:

Organobalance GmbH is a biotechnology research and development company with facilities in Berlin and Flensburg. Founded in 2001, the firm develops and markets products based on probiotic bacteria cultures as well as yeast production strains for use in industrial biotechnology. One of its best-known products is Pylopass™, a natural lactobacillus agent which acts highly specific against Helicobacter pylori, a stomach bacterium. Among the company's German and international customers are clients from the food, cosmetics, feed, agriculture, and pharmaceutical industries. The company owns an extensive collection of yeast and lactobacillus cultures, some of which date back to the 1920s. Organobalance has been a part of the Danish company Novozymes A/S since September 2016, www.organobalance.de

For further information:

Novozymes / Organobalance
Gustav-Meyer-Allee 25
13355 Berlin, Germany
Phone +49 (0) 30 9210765 50
Fax +49 (0) 30 46307 210
www.organobalance.de